To­tus Med­i­cines clos­es $66M Se­ries B to fund ear­ly-stage PI3Ka in­hibitor, names new CEO

Small mol­e­cule biotech To­tus Med­i­cines has closed a $66 mil­lion Se­ries B to car­ry its PI3Kα in­hibitor through Phase Ia and has named Nas­sim Us­man as its new pres­i­dent and CEO.

The Emeryville, CA-based To­tus, which emerged with a $40 mil­lion Se­ries A in De­cem­ber 2021, closed the Se­ries B in re­cent weeks af­ter Us­man joined, he told End­points News. He re­places found­ing CEO Neil Dhawan, who will re­main as chief sci­en­tif­ic of­fi­cer and add on head of R&D re­spon­si­bil­i­ties, To­tus said Fri­day morn­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER